Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Dose Comparison in Advanced Breast Cancer
NCT00026442Phase 2Unknown
- Sponsor
- Pharmatech Oncology
- Start
- Nov 2001
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine in breast cancer (2 arms), sponsored by Pharmatech Oncology. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00026442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026442.